Rapid regression of atherosclerosis induced by liver-directed gene transfer of apoE in apoE-deficient mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 9, 1999, Pages 2162-2170

  Tsukamoto, Kazuhisa ^a   Tangirala, Rajendra ^a   Chun, Sam H ^b   Puré, Ellen ^b   Rader, Daniel J ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adenoviral vectors; Apolipoproteins; Atherosclerosis; Gene transfer; Regression

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; CHOLESTEROL; LIPID; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; FOAM CELL; GENE TRANSFER; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS RECOMBINANT;

EID: 0032830257     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.9.2162     Document Type: Article

References (58)

1. Tucker CF, Catsulis C, Strong JP, Eggen DA. Regression of early cholesterol-induced aortic lesions in Rhesus monkeys. Am J Pathol. 1971; 65:493-514.
2. Armstrong ML, Megan MB. Arterial fibrous proteins in cynomolgus monkeys after atherogenic and regression diets. Circ Res. 1975;36: 256-261.
3. Daoud A. Jamolych J, Augustyn J, Fritz K, Singh J, Lee KT. Regression of advanced atherosclerosis in swine. Arch Pathol Lab Med. 1976;100: 372-379.
4. Small DM, Bond MG, Waugh D, Prack M, Sawyer JK. Physicochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis. J Clin Invest. 1984;73: 1590-1605.
5. Clarkson TB, Bond M, Bullock B, McLaughlin K, Sawyer JK. A study of atherosclerosis regression in Macaca mulatta. Exp Mol Pathol. 1984;41: 96-118.
6. Moncada S, Martin J, Higgs A. Symposium on regression of atherosclerosis. Eur J Clin Invest. 1993;23:385-398.
7. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87:1781-1791.
8. Fuster V, Fallon JT, Badimon JJ, Nemerson Y. The unstable atherosclerotic plaque: clinical significance and therapeutic intervention. Thromb Haemost. 1997;78:247-255.
9. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622-630.
10. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71:343-353.
11. Zhang S, Reddick R, Piedrahita J, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468-471.
12. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994;14:133-140.
13. Breslow JL. Mouse models of atherosclerosis. Science. 1996;272: 685-688.
14. Kashyap VS, Santamarina-Fojo S, Brown DR, Parrott CL, Applebaum-Bowden D, Meya S, Talley G, Paigen B, Maeda N, Brewer HB Jr. Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors. J Clin Invest. 1995;96: 1612-1620.
15. Stevenson S, Marshall-Neff J, Teng B, Lee C, Roy S, McClelland A. Phenotypic correction of hypercholesterolemia in apoE-deficient mice by adenovirus-mediated in vivo gene transfer. Arterioscler Thromb Vasc Biol. 1995;15:479-484.
16. Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science. 1995;267:1034-1037.
17. Boisvert W, Spangenberg J, Curtiss L. Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation. J Clin Invest. 1995;96:1118-1124.
18. Bellosta S, Mahley RW, Sanan DA, Murata J, Newland DL, Taylor JM, Pitas RE. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest. 1995;96:2170-2179.
19. Fazio S, Babaev V, Murray A, Hasty AH, Carter KJ, Gleaves LA, Atkinson JB, Linton MF. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proc Natl Acad Sci U S A. 1997;94:4647-4652.
20. Huang Y, von Eckardstein A, Wu S, Maeda N, Assmann G. A plasma lipoprotein containing only apolipoprotein E and with γ mobility on electrophoresis releases cholesterol from cells. Proc Natl Acad Sci U S A. 1994;91:1834-1838.
21. Krimbou L, Tremblay M, Davignon J, Cohn J. Characterization of human plasma apolipoprotein E-containing lipoproteins in the high density lipoprotein size range: focus on pre-B1-LpE, pre-B2-LpE, and a-LpE. J Lipid Res. 1997;38:35-48.
22. Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem. 1982;257: 2518-2521.
23. Lalazar A, Weisgraber KH, Rall SC Jr, Giladi H, Innerarity TL, Levanon AZ, Boyles JK, Amit B, Gorecki M, Mahley RW, et al. Site-specific mutagenesis of human apolipoprotein E: receptor binding activity of variants with single amino acid substitutions. J Biol Chem. 1988;263: 3542-3545.
24. Gregg RE, Zech LA, Schaefer EJ, Brewer HB Jr. Type III hyperlipoproteinemia: defective metabolism of an abnormal apolipoprotein E. Science. 1981;211:584-586.
25. Brewer HB Jr, Zech LA, Gregg RE, Schwartz D, Schaefer EJ. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. Ann Intern Med. 1983;98:623-640.
26. Gregg RE, Zech LA, Schaefer EJ, Stark D, Wilson D, Brewer HB Jr. Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest. 1986;78:815-821.
27. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988;8:1-21.
28. Wilson PWF, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. JAMA. 1994;272:1666-1671.
29. Huang Y, von Eckardstein A, Wu S, Assmann G. Effects of the apolipoprotein E polymorphism on uptake and transfer of cell-derived cholesterol in plasma. J Clin Invest. 1995;96:2693-2701.
30. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science. 1994;264:850-852.
31. Nathan BP, Chang KC, Bellosta S, Brisch E, Ge N, Mahley RW, Pitas RE. The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. J Biol Chem. 1995;270: 19791-19799.
32. Bellosta S, Nathan B, Orth M, Dong L, Mahley R, Pitas R. Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J Biol Chem. 1995;270:27063-27071.
33. Tsukamoto K, Smith P, Glick JM, Rader DJ. Liver-directed gene transfer and prolonged expression of three major human apoE isoforms in apoE deficient mice. J Clin Invest. 1997;100:107-114.
34. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA. 1994; 91:6196-6200.
35. Ye X, Robinson M, Batshaw M, Furth E, Smith I, Wilson JM. Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors. J Biol Chem. 1996;271:3639-3646.
36. Tsukamoto K, Watanabe T, Matsushima T, Kinoshita M, Kato H, Hashimoto Y, Kurokawa K, Teramoto T. Determination by PCR-RFLP of apo E genotype in a Japanese population. J Lab Clin Med. 1993;121: 598-602.
37. Kowala MC, Mazzucco CE, Hartl KS, Seiler SM, Warr GA, Abid S, Grove RJ. Prostacyclin agonists reduce early atherosclerosis in hyperlipidemic hamsters. Arterioscler Thromb. 1993;13:435-444.
38. Kowala MC, Rose PM, Stein PD, Goller N, Reece R, Beyer S, Valentine M, Barton D, Durham SK. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Pathol. 1995;146:819-826.
39. Metlay JP, Witmer-Pack MD, Agger R, Crowley MT, Lawless D, Steinman RM. The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal antibodies. J Exp Med. 1990;171:1753-1771.
40. Paigen B, Morrow A, Holmes PA, Mitchell D, William RA. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 1987;68: 231-240.
41. Rubin E, Krauss R, Spangler E, Verstuyft J, Clift S. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353:265-267.
42. Plump A, Scott C, Breslow J. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA. 1994;91: 9607-9611.
43. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest. 1994;94:899-903.
44. Gerdes LU, Gerdes C, Klausen IC, Faergeman O. Generation of analytic plasma lipoprotein profiles using two prepacked Superose 6B columns. Clin Chim Acta. 1992;205:1-9.
45. Lever MJ, Jay MT, Coleman PJ. Plasma protein entry and retention in the vascular wall: possible factors in atherogenesis. Can J Physiol Pharmacol. 1996;74:818-823.
46. Huang Y, Zhu Y, Raabe M, Raabe M, Wu S, Wiesenbutter B, Seedorf U, Maeda N, Assmann G, von Eckardstein A. Effects of genotype and diet on cholesterol efflux into plasma and lipoproteins of normal, apolipoprotein A-I-, and apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 1997;17:2010-2019.
47. Zhu Y, Bellosta S, Langer C, Bernini F, Pitas RE, Mahley RW, Assmann G, von Eckardstein A. Low-dose expression of a human apolipoprotein E transgene in macrophages restores cholesterol efflux capacity of apolipoprotein E-deficient mouse plasma. Proc Natl Acad Sci U S A. 1998;95: 7585-7580.
48. Ji ZS, Brecht WJ, Miranda RD, Hussain MM, Innerarity TL, Mahley RW. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J Biol Chem. 1993;268:10160-101167.
49. Zhong-Sheng J, Pitas RE, Mahley RW. Differential cellular accumulation/retention of apolipoprotein E mediated by cell surface heparan sulfate proteoglycans. J Biol Chem. 1998;273:13452-13460.
50. Huang DY, Weisgraber KH, Strittmatter WJ, Matthew WD. Interaction of apolipoprotein E with laminin increases neuronal adhesion and alters neunte morphology. Exp Neurol. 1995;136:251-257.
51. Mazzone T. Apolipoprotein E secretion by macrophages: its potential physiological functions. Curr Opin Lipidol. 1996;7:303-307.
52. Hara H, Yokoyama S. Interaction of free apolipoproteins with macrophages: formation of high density lipoprotein-like lipoproteins and reduction of cellular cholesterol. J Biol Chem. 1991;266:3080-3086.
53. Zhang W-Y, Paulette M, Kruth HS. Apolipoprotein E produced by human monocyte-derived macrophages mediates cholesterol efflux that occurs in the absence of added cholesterol acceptors. J Biol Chem. 1996;271: 28641-28646.
54. Smith J, Miyata M, Ginsberg M, Grigaux C, Shmookler E, Plump A. Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors. J Biol Chem. 1996;271:30647-30655.
55. Riddell DR, Graham A, Owen JS. Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway: implications for vascular disease. J Biol Chem. 1997;272:89-95.
56. Kelly ME, Clay MA, Mistry MJ, Hsieh-Li HM, Harmony JA. Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity. Cell Immunol. 1994;159:124-139.
57. Browning P, Roberts D, Zabrentzky V, Bryant J, Kaplan M, Washington RH, Panet A, Gallo RC, Vogel T. Apolipoprotein E (apoE), a novel heparin-binding protein inhibits the development of Kaposi's sarcoma-like lesions in BALB/c nu/nu mice. J Exp Med. 1994;180: 1949-1954.
58. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides. Nat Genet. 1996;14:55-61.